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Paclitaxel is a chemotherapeutic drug commonly used to treat different types of cancer. In
addition to its antitumor effect, paclitaxel is also known to promote Toll-like receptor (TLR)
4-dependent inflammatory responses, which may lower its chemotherapeutic efficacy.
However, it remains unclear whether paclitaxel is able to affect inflammasome signaling
in myeloid or cancer cells. Therefore, we examined the potential effect of paclitaxel
on the activation of an inflammasome complex by examining caspase-1 activation
and interleukin (IL)-1β secretion in bone marrow-derived macrophages (BMDMs). The
results showed that treatment with paclitaxel alone or following LPS priming failed to
trigger the secretion of active caspase-1 and IL-1β from BMDMs. However, paclitaxel
could induce robust activation of caspase-1 in BMDMs in the presence of NLRP3
inflammasome-activating signal 2, such as ATP or nigericin. This paclitaxel/ATP-mediated
inflammasome activation was completely abrogated in Nlrp3-deficient macrophages.
Mechanistically, paclitaxel treatment induced robust activation of the TLR4 signaling
cascade, including phosphorylation of IκB and JNK and upregulation of proinflammatory
cytokine mRNA levels in a TLR4-dependent manner. In contrast, paclitaxel treatment
alone did not induce mitochondrial damages such as the loss of the mitochondrial
membrane potential and production of mitochondrial ROS. These findings suggest
that paclitaxel can drive the priming of signal-mediated events for NLRP3 activation
but not a second signal-triggered phenomenon such as mitochondrial damage. This
suggestion was supported by the observations that paclitaxel treatment caused robust
IL-1β production in macrophages in the presence of cell-free medium derived from
growth of injured cells and also in the spleen of mice. Collectively, our data strongly
indicate that paclitaxel is able to facilitate the activation of NLRP3 inflammasome signaling
in a certain physiological environment.
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INTRODUCTION
Paclitaxel is a common chemotherapeutic drug used for treating a wide range of solid tumors,
including lung, ovarian, and breast cancers (1). Although the precise mechanism of its cytotoxicity
is still debatable, microtubule stabilization is considered the main mode of action of paclitaxel
(1, 2). Paclitaxel-stabilized microtubules may interfere with normal mitosis, eventually leading to
apoptotic cell death (2).
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In addition to its chemotherapeutic effect, paclitaxel has
been demonstrated to induce inflammation in myeloid or
cancer cells and in the paclitaxel-treated patients (3–6). In
particular, paclitaxel is known to trigger the production
of proinflammatory cytokines such as interleukin (IL)-6
and IL-8 via binding to Toll-like receptor 4 (TLR4) on
myeloid cells and many cancer cells (7). Of note, paclitaxel-
induced inflammation often contributes to tumor proliferation,
invasion, and chemoresistance during paclitaxel treatment (7–
9). Meanwhile, a recent study has proposed that paclitaxel
reprogramsM2-polarized tumor-associated macrophages to M1-
like phenotype in a TLR4-dependent manner, and this M1-
like phenotype contributes to the antitumor effect of paclitaxel
(10). Hence, the molecular mechanism of paclitaxel-induced
inflammation needs to be further elucidated to understand the
efficacy of paclitaxel chemotherapy.
The TLR4-NF-κB signaling axis is considered the main
pathway for paclitaxel-induced production of proinflammatory
cytokines (7). Most proinflammatory cytokines are released from
myeloid and non-myeloid cells upon activation of TLR4-NF-
κB pathways. However, active IL-1β, a key proinflammatory
cytokine, can only be secreted upon the formation of an
intracellular inflammasome complex (11, 12). Interestingly, IL-
1β may promote tumorigenesis and tumor invasion (13), and
the blockade of the IL-1 receptor by an IL-1R antagonist
was shown to improve the anti-tumor effect of chemotherapy
(14, 15). Therefore, it seems intriguing to examine whether
paclitaxel treatment facilitates the assembly and activation of an
inflammasome complex and subsequent secretion of IL-1β.
The inflammasome complex comprises of sensor molecules
such as NOD-like receptor (NLR) family, pyrin domain-
containing 3 (NLRP3) or NLR family, card domain-containing
4 (NLRC4), apoptosis-associated speck-like protein containing
a caspase recruitment domain (ASC), and procaspase-1 (12).
In a resting state, sensor molecules are thought to be inactive
and thus incapable of binding to the ASC protein (16).
Upon stimulation with inflammasome-activating signals, sensor
molecules may be converted into an active form and assemble an
inflammasome complex, which leads to the activation of caspase-
1. Subsequently, active caspase-1 processes inactive pro-IL-1β
into an active mature form (17). Some previous reports have
demonstrated that paclitaxel treatment led to the increased IL-1β
mRNA production and protein secretion (18, 19). However, the
inflammasome/caspase-1-activating capacity of paclitaxel has not
been carefully studied yet. Here, we examined whether paclitaxel
is able to drive the assembly of the inflammasome complex and
activation of caspase-1 in macrophages.
MATERIALS AND METHODS
Reagents and Antibodies
Paclitaxel, doxorubicin, etoposide, LPS, ATP, nigericin,
staurosporine, glibenclamide, and valiomycin were purchased
from Sigma-Aldrich. Ciliobrevin D and SP600125 were
purchased from Calbiochem. JC-1 and MitoSOX were purchased
from Invitrogen. Alum was purchased from InvivoGen. Anti-
mouse caspase-1, anti-NLRP3 and anti-ASC antibodies were
obtained from AdipoGen. Anti-mouse IL-1β antibody was
obtained from R&D Systems. Anti-phospho-IκB and anti- IκB
antibodies were purchased from Cell Signaling Technology.
Anti-phospho-JNK and anti-JNK antibodies were obtained from
Invitrogen and BD, respectively. Anti-β-actin antibody was
purchased from Santa Cruz Biotechnology.
Mice and Cell Cultures
C57BL/6, Nlrp3−/−, and Tlr4−/− mice were obtained from
The Jackson Laboratory. All mice were maintained under
specific pathogen-free conditions and 9∼15-weeks-oldmalemice
were used for experiments. In some experiments, mice were
intraperitoneally injected with PBS or paclitaxel (40 mg/kg) and
sacrificed 24 h post-injection. Mouse bone marrow cells were
prepared from the femurs of C57BL/6, Nlrp3−/−, and Tlr4−/−
mice and cultured in DMEM supplemented with L929 culture
supernatants for 5∼7 days to differentiate into bone marrow-
derived macrophages (BMDMs). Protocols for the animal
experiments (2017-0221) were approved by the Institutional
Ethical Committee, Yonsei University College of Medicine. All
experiments were performed in accordance with the approved
guidelines of the Institutional Ethical Committee. BMDMs were
maintained in L929-conditioned DMEM supplemented with
10% FBS and antibiotics. A549 cells were grown in DMEM
supplemented with 10% FBS and antibiotics.
Immunoblot Analysis
Cells were lysed in buffer containing 20mM HEPES (pH
7.5), 0.5% Nonidet P-40, 50mM KCl, 150mM NaCl, 1.5mM
MgCl2, 1mM EGTA, and protease inhibitors. Soluble lysates
were fractionated by SDS-PAGE, and separated proteins were
transferred to PVDF membranes. In some experiments, cell
culture supernatants were precipitated by methanol/chloroform
as described previously (20) and then immunoblotted. All the
blots shown are representative images from at least three-
independent experiments.
mRNA Quantification
To measure mRNA expression, total RNA was isolated from
cells using a TRIzol reagent (Invitrogen) and reverse transcribed
using PrimeScript RT Master Mix (Takara). Quantitative PCR
was performed using SYBR Premix Ex Taq (Takara) and the
following primers: 5′-GCC CAT CCT CTG TGA CTC AT-3′ and
5′-AGG CCA CAG GTA TTT TGT CG-3′ (mouse Il-1β); 5′-
AGT TGC CTT CTT GGG ACT GA-3′ and 5′-TCC ACG ATT
TCC CAG AGA AC-3′ (mouse Il-6); 5′- ATG CTG CTTCGA
CAT CTC CT-3′ and 5′-AAC CAA TGC GAG ATC CTG AC-
3′ (mouse Nlrp3); and 5′-CGC GGT TCT ATT TTG TTG GT-3′
and 5′-AGT CGG CAT CGT TTA TGG TC-3′ (mouse Rn18s).
Assay of Inflammasome Activation and
Cell Death
To stimulate the conventional NLRP3 inflammasome activation,
BMDMs were primed with LPS (0.25µg/mL, 3 h), followed
by treatment with ATP (2.5mM, 30min), nigericin (5µM,
40min) or alum (250µg/mL, 6 h). Inflammasome activation was
determined by the presence of protein bands corresponding to
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active caspase-1 p20 and active IL-1β band in immunoblots of
culture supernatants. To measure extracellular levels of IL-1β or
IL-6, culture supernatants were assayed using an IL-1β- or IL-6-
specific ELISA kit (BioLegend) according to the manufacturer’s
instructions. Caspase-1-dependent cell death was determined
by extracellular release of lactate dehydrogenase (LDH) using a
CytoTox96 non-radioactive cytotoxicity assay kit (Promega). The
LDH release was calculated as [extracellular LDH/(intracellular
LDH+ extracellular LDH)× 100].
Assay of Inflammasome Assembly
To determine the oligomerization of ASC, a discuccinimidyl
suberate (DSS; Thermo Scientific)-mediated cross-linking assay
was performed as described previously (21). To visualize
molecular interactions of NLRP3 with ASC, a proximity-ligation
(PL) assay was performed using the Duolink in situ Red
starter kit (Sigma) with an anti-ASC and anti-NLRP3 antibodies
according to the manufacturer’s protocols. The relative number
of PL signal-positive cells was quantified using the Image
J software.
Measurement of Mitochondrial Membrane
Potential and Mitochondrial ROS
Production
To measure the mitochondrial membrane potential, cells
were stained with the membrane potential-sensitive JC-
1 dye, which forms red fluorescence-emitting aggregates
on polarized mitochondria and green fluorescence-
emitting monomers on depolarized mitochondria. Cells
were analyzed by flow cytometry using FL1 and FL2
channels. To measure mitochondrial ROS production levels,
mouse BMDMs were stained with MitoSOX (Invitrogen)
after appropriate treatments. Cells were then analyzed
by flow cytometry (FACSVerse, BD) based on the level
of MitoSOX.
Cultures in Conditioned Medium
To examine the effects of damaged cell-derived factors, A549
cells were first treated with staurosporine (1µg/mL) for
24 h, then washed with PBS, and incubated with fresh Opti-
MEM for an additional 18 h. The cell-free culture medium
was then collected from the A549 cells and mixed with
BMDM culture medium (2:1 ratio). This conditioned medium
was added to BMDMs, and its effects were assayed in
appropriate experiments.
Statistical Analysis
All values were expressed as the mean ± SEM of individual
samples. Data were analyzed using one-way analysis of
variance followed by Dunnett’s post-hoc test for multiple
comparisons of all groups with the control group or
two-way analysis of variance with Bonferroni post-hoc
test for comparisons between untreated and paclitaxel-
treated groups.. The level of statistical significance
was set at P ≤ 0.05. Analyses were performed using
GraphPad Prism.
RESULTS
Paclitaxel Promotes Secretion of
Interleukin-1β From Macrophages Upon
Costimulation With ATP
To first examine whether chemotherapeutic drugs could
induce the secretion of pro-inflammatory cytokines from
macrophages, three common anti-tumor drugs, doxorubicin,
etoposide, and paclitaxel, were used to treat BMDMs.
Among the tested drugs, only paclitaxel caused considerable
production of IL-6 in BMDMs (Figure 1A). However, no
chemotherapeutic drug further increased the LPS-triggered
IL-6 production (Figure 1B). Subsequently, we examined
whether these anti-tumor drugs could mediate the activation
of inflammasome signaling, as measured by IL-1β secretion.
With LPS priming, all the tested drugs failed to promote
the significant secretion of IL-1β in BMDMs (Figure 1C).
Meanwhile, with ATP costimulation, paclitaxel-, but not
doxorubicin or etoposide induced robust secretion of
IL-1β from BMDMs (Figure 1D). This finding raises a
possibility that paclitaxel treatment can trigger inflammasome
activation and IL-1β secretion from macrophages under
certain conditions.
Paclitaxel Promotes NLRP3-Dependent
Caspase-1 Activation in the Presence of an
NLRP3-Activating Second Signal
Thereafter, we examined whether paclitaxel indeed drives
caspase-1 activation in macrophages, as determined by the
presence of active caspase-1 (p20) in culture supernatants.
Consistent with the data shown in Figure 1D, paclitaxel
treatment induced robust activation of caspase-1 and
subsequent secretion of active IL-1β in BMDMs only with
ATP costimulation (Figures 2A,B) but not following LPS
priming (Figure 2C). Generally, ATP is considered a common
second signal for NLRP3 inflammasome activation, which
requires two independent signals, a priming signal 1 such as
LPS and an activation signal 2 such as ATP (22). Therefore,
we further tested whether paclitaxel can activate caspase-
1 in the presence of another NLRP3 activation signal
2, such as nigericin or alum crystals, and demonstrated
that costimulation with nigericin or alum after paclitaxel
treatment also led to robust activation of caspase-1 and
IL-1β (Figures 2D,E).
We then explored the NLRP3 dependency of paclitaxel-
induced inflammasome activation. Paclitaxel plus ATP
stimulation induced strong activation of caspase-1 and IL-
1β in Nlrp3-expressing but not in Nlrp3-deficient BMDMs
(Figure 2F). In addition, treatment with paclitaxel alone
did not cause a significant cell death of BMDMs in our
experimental settings, whereas paclitaxel treatment, followed
by ATP stimulation, resulted in a considerable cell death
(Figure 2G). This paclitaxel/ATP-mediated cell death was
not observed in Nlrp3-deficient BMDMs (Figure 2G).
These findings indicate that paclitaxel/ATP treatment is
able to promote NLRP3 inflammasome activation and
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FIGURE 1 | Paclitaxel treatment promotes secretion of proinflammatory cytokines from BMDMs. (A) Quantification of IL-6 in culture supernatants of mouse BMDMs
untreated (Unt) or treated with doxorubicin (Dox, 10 or 100µM), etoposide (VP-16, 50, or 200µM), paclitaxel (PX, 5, or 20µM) or LPS (0.25µg/mL) for 3 h (n = 3).
(B) Quantification of IL-6 in culture supernatants of mouse BMDMs primed with LPS (0.25µg/mL) for 3 h, followed by treatment with doxorubicin (100µM), paclitaxel
(20µM) or etoposide (200µM) for 6 h (n = 2). (C) Quantification of IL-1β in culture supernatants of mouse BMDMs primed with LPS (0.25µg/mL, 3 h), followed by
treatment with doxorubicin (10 or 100µM), etoposide (50 or 200µM), and paclitaxel (5 or 20µM) for 3 h or ATP (2.5mM) for 30min (n = 2–4). (D) Quantification of
IL-1β in culture supernatants of mouse BMDMs treated with doxorubicin (10 or 100µM), etoposide (50 or 200µM), paclitaxel (5 or 20µM) or LPS (0.25µg/ml) for 3 h,
followed by treatment with ATP (2.5mM, 30min) (n = 4). Data were expressed as the mean ± SEM. Asterisks indicate significant differences (*P < 0.05, **P < 0.01,
***P < 0.001).
a subsequent caspase-1-dependent pyroptotic cell death
of macrophages.
Paclitaxel Treatment, Followed by ATP
Costimulation, Promotes Assembly of the
NLRP3 Inflammasome.
Next, we examined whether paclitaxel/ATP treatment indeed
drives the assembly of the NLRP3 inflammasome. Potassium
(K+) eﬄux is considered an essential upstream requirement for
NLRP3 inflammasome assembly (23). Inhibition of K+ eﬄux
by glibenclamide or extracellular KCl treatment completely
blocked caspase-1 activation by paclitaxel/nigericin treatment
(Figure 3A), indicating that K+ eﬄux was mediated by
paclitaxel-induced inflammasome assembly. Consistently,
paclitaxel/ATP treatment caused strong oligomerization of
ASC, as determined by the DSS-mediated cross-linking assay
(Figure 3B). In addition, paclitaxel treatment with ATP
costimulation increased the protein-protein interaction between
NLRP3 and ASC, as measured by PL assay (Figures 3C,D).
These observations demonstrated that paclitaxel could facilitate
the K+ eﬄux-dependent assembly of the NLRP3 inflammasome
in macrophages, as shown by the interaction of NLRP3 with ASC
and ASC oligomerization.
Paclitaxel Mediates Transcriptional
Induction of Proinflammatory Cytokines in
a TLR4-Dependent Manner
To understand how paclitaxel treatment drives activation of the
NLRP3 inflammasome, we first examined the requirement for
TLR4 signaling. Previous studies have reported that paclitaxel
induced TLR4-mediated signaling in many cancer cells (7, 8). It
was of particular interest that paclitaxel/ATP-induced caspase-
1 activation and IL-1β secretion was completely abrogated in
Tlr4-deficient BMDMs (Figure 4A). Similar to its effect on IL-1β
secretion, paclitaxel treatment led to the secretion of IL-6 in wild-
type BMDMs but not in Tlr4-deficient macrophages (Figure 4B).
Indeed, paclitaxel induced a robust mRNA expression of Il-6,
Il-1β , and Nlrp3 in a TLR4-dependent manner (Figures 4C–E).
However, paclitaxel-promoted production of IL-6 protein and
mRNA was independent of NLRP3 presence (Figure 4F and
Supplementary Figure 1). These results strongly support the
hypothesis that paclitaxel can induce robust transcription of
proinflammatory cytokines in a TLR4-dependent manner.
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FIGURE 2 | Paclitaxel treatment facilitates NLRP3-dependent caspase-1 activation in BMDMs. (A) Immunoblots from mouse BMDMs untreated (Unt) or treated with
paclitaxel (PX, 5µM) or LPS (0.25µg/mL) for 3 h, followed by treatment with ATP (2.5mM, 30min), as indicated. (B) Immunoblots from mouse BMDMs untreated
(Unt) or treated with paclitaxel (PX, 1∼20µM) or LPS (0.25µg/mL) for 3 h, followed by treatment with ATP (2mM, 30min). (C) Immunoblots from mouse BMDMs
untreated (Unt) or treated with paclitaxel (PX, 5µM), doxorubicin (Dox, 10µM) or etoposide (VP-16, 50µM) alone for 6 h, or 3 h with LPS pretreatment (0.25µg/mL,
3 h) or with ATP post-treatment (2.5mM, 30min), as well as with LPS, followed by ATP treatment. (D) Immunoblots from mouse BMDMs untreated (Unt) or treated
with paclitaxel (PX, 5µM) or LPS (0.25µg/mL) for 3 h, followed by treatment with ATP (2mM, 30min), nigericin (Nig, 5µM, 40min), or alum (250µg/mL, 7 h), as
indicated. (E) Quantification of IL-1β in culture supernatants of mouse BMDMs treated with paclitaxel (PX, 5µM, 3 h) in the presence of LPS pretreatment (0.5µg/mL,
3 h), or treated with paclitaxel or LPS, followed by ATP (3mM, 30min) or nigericin (Nig, 5µM, 40min) (n = 3–4). (F) Immunoblots from Nlrp3+/+ or Nlrp3−/− mouse
BMDMs treated with paclitaxel (5µM, 3 h), or LPS (0.25µg/mL, 3 h), followed by ATP treatment (2mM, 30min). (G) LDH release into culture supernatants of
Nlrp3+/+ (n = 3) or Nlrp3−/− (n = 2) mouse BMDMs treated with paclitaxel (PX, 1, 5 or 20µM, 3 h), followed by treatment with ATP (2mM, 30min). (A–D,F) Culture
supernatants (Sup) or cell lysates (Lys) were immunoblotted with the indicated antibodies. (E,G) Asterisks indicate significant differences (*P < 0.05, ***P < 0.001).
Paclitaxel Mediates JNK-Implicating
Non-transcriptional Priming of NLRP3
Inflammasome Activation
We then examined TLR4 downstream signaling pathways,
such as NF-κB and MAP kinase signaling, in macrophages upon
paclitaxel stimulation. Similar to LPS treatment, paclitaxel caused
robust phosphorylation and degradation of IκB (Figure 5A),
indicating that paclitaxel treatment led to the activation of
NF-κB pathways in macrophages. In addition, paclitaxel
drove robust phosphorylation of JNK in BMDMs (Figure 5B).
NLRP3 inflammasome activation requires non-transcriptional
priming steps downstream of TLR (24–27). A recent study
has suggested that TLR4-mediated activation of JNK signaling
pathways is an essential non-transcriptional priming step
for NLRP3 activation (28). Interestingly, the JNK-selective
inhibitor SP600125 remarkably blocked paclitaxel-induced
IκB phosphorylation in BMDMs (Figure 5C). Furthermore,
SP600125 clearly abolished paclitaxel/ATP-triggered caspase-1
activation (Figure 5D). These data support the hypothesis that
paclitaxel-mediated JNK signaling is potentially implicated in the
non-transcriptional priming step of paclitaxel-mediated NLRP3
inflammasome activation.
Given that mitochondrial damage may contribute to the
priming or activation of NLRP3 inflammasome (16, 29), we
then examined whether paclitaxel treatment could induce
mitochondrial impairments, by measuring the loss of the
mitochondrial membrane potential and the production of
mitochondrial ROS. The results showed that paclitaxel/ATP
treatment resulted in a reduced mitochondrial membrane
potential (75.5–56.8%), as demonstrated by JC-1 staining,
but this reduction was due to ATP treatment rather that
to treatment with paclitaxel alone (Figure 6A). Similarly,
treatment with ATP alone led to an increase in mitochondrial
ROS production, whereas paclitaxel treatment did not
change the levels of mitochondrial ROS (Figures 6B,C and
Supplementary Figure 2). These observations demonstrated
that mitochondrial damages were mainly induced by
NLRP3-activating second signals, such as ATP, but not by
paclitaxel treatment. On the other hand, the inhibition of
mitochondrial transport by ciliobrevin D markedly blocked
paclitaxel/ATP-mediated caspase-1 activation (Figure 6D).
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FIGURE 3 | Paclitaxel treatment in the presence of an NLRP3 agonist promotes the assembly of the NLRP3 inflammasome. (A) Immunoblots from mouse BMDMs
untreated (Unt) or primed with LPS (0.25µg/mL, 3 h) or paclitaxel (5µM, 3 h) in the presence of glibenclamide (100µM) or KCl (30mM), followed by treatment with
nigericin (5µM, 40min). Culture supernatants (Sup) or cell lysates (Lys) were immunoblotted with the indicated antibodies. (B) Immunoblots of disuccinimidyl suberate
(DSS)-crosslinked pellets (DSS-pel), cellular lysates (Lys) or cultural supernatants (Sup) from mouse BMDMs treated with LPS (0.25µg/mL, 3 h) or paclitaxel (5µM,
3 h), followed by treatment with ATP (3mM, 30min). (C) Proximity ligation (PL) assay of NLRP3 and ASC in mouse BMDMs treated with paclitaxel (PX, 5µM, 3 h) or
LPS (0.25µg/mL, 3 h), followed by treatment with ATP (2.5mM, 30min). PL signals (red) represent the molecular association of NLRP3 and ASC. Data are shown as a
representative image from five-independent samples. Scale bars, 10µm. (D) Relative percentages of PL signal-positive cells (n = 5). Data are expressed as the mean
± SEM. Asterisks indicate significant differences (*P < 0.05, **P < 0.01).
Meanwhile, a recent our previous study has shown that
mitochondrial transport is also driven by ATP treatment
(30). These findings further support the hypothesis that
paclitaxel does not function as an activation signal 2 for NLRP3
inflammasome activation.
Paclitaxel-Induced Priming Triggers
Interleukin-1β Secretion Upon
Costimulation With Products Released
From Damaged Cells
Extracellular ATP is considered a main danger signal released
from dead or injured cells (31). To examine whether culture
supernatants from injured cells can facilitate the paclitaxel-
primed inflammasome activation, A549 cells were treated
with staurosporine to induce a robust cell death. Then, the
cultural supernatants from staurosporine-treated A549 cells
were collected and used to treat unprimed or paclitaxel-primed
BMDMs. Similar levels of IL-1β were detected from culture
supernatants of staurosporine-treated A549 cells, compared with
that of untreated A549 cells (Figure 7A). On the contrast,
there was a slight increase in IL-6 production from A549 cells
by the treatment of staurosporine (Figure 7B). Intriguingly,
supernatants of the staurosporine-treated cultures promoted
robust IL-1β secretion by paclitaxel-primed BMDMs but not by
unprimed BMDMs (Figure 7A). However, culture supernatants
from staurosporine-treated A549 cells alone failed to induce the
production of IL-1β and IL-6 mRNA in BMDMs (Figures 7C,D).
These data indicate that paclitaxel provides a priming signal, and
products released from damaged cells, possibly containing ATP,
can function as an activation signal for the NLRP3 inflammsome
activation in our experimental settings.
To test whether paclitaxel treatment can induce
inflammasome activation in vivo, mice were intraperitoneally
challenged with paclitaxel. Consequently, paclitaxel-treated
wild-type mice showed a marked increase in the level of IL-1β
in the spleen, whereas Nlrp3-deficient mice did not show any
changes in the IL-1β levels (Figure 7E). Paclitaxel administration
also increased the IL-6 levels in the spleen of wild-type mice
but not of Nlrp3−/− mice (Figure 7F). All the findings strongly
demonstrate that the administration of the chemotherapeutic
drug paclitaxel is able to promote the priming and activation of
NLRP3 inflammasome signaling, which may affect the efficacy of
paclitaxel, depending on the adjacent conditions.
DISCUSSION
Many chemotherapeutic agents have been previously shown
to induce the production of proinflammatory cytokines in
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FIGURE 4 | Paclitaxel treatment promotes TLR4-dependent inflammasome activation and proinflammatory cytokine production. (A) Immunoblots of cultural
supernatants (Sup) or cellular lysates (Lys) from Tlr4+/+ or Tlr4−/− mouse BMDMs treated with paclitaxel (PX, 5µM, 3 h) or LPS (0.25µg/mL, 3 h), followed by ATP
treatment (3mM, 30min). (B) Quantification of IL-6 in culture supernatants of Tlr4+/+ or Tlr4−/− mouse BMDMs treated with paclitaxel (5 or 10µM, 3 h) or LPS
(0.5µg/mL, 3 h) (n = 3). (C–E) Quantification of Il-6 (C), Il-1β (D), or Nlrp3 (E) mRNA levels in Tlr4+/+ or Tlr4−/− mouse BMDMs treated with paclitaxel (5 or 10µM,
3 h) or LPS (0.5µg/mL, 3 h) (n = 3–6). (F) Quantification of IL-6 in culture supernatants of Nlrp3+/+ or Nlrp3−/− mouse BMDMs treated with paclitaxel (5 or 10µM,
3 h) or LPS (0.5µg/mL, 3 h) (n = 3). Data are expressed as the mean ± SEM. Asterisks indicate significant differences (*P < 0.05, **P < 0.01, ***P < 0.001, n.s., not
significant).
FIGURE 5 | Paclitaxel mediates JNK signaling-dependent priming of NLRP3 inflammasome activation. (A) Immunoblots of cellular lysates from mouse BMDMs
untreated (Unt) or treated with paclitaxel (5µM) or LPS (0.25µg/mL) for 15, 30, or 60min. (B) Immunoblots of cellular lysates from mouse BMDMs treated with
paclitaxel (5µM) or LPS (0.5µg/mL) for 3 h. (C) Immunoblots of cultural supernatants or cellular lysates from mouse BMDMs treated with paclitaxel (5µM, 3 h) or LPS
(0.25µg/mL, 3 h) after pretreatment with SP600125 (20µM, 30min). (D) Immunoblots of cultural supernatants or cellular lysates from mouse BMDMs treated with
paclitaxel (5µM, 3 h) or LPS (0.25µg/mL, 3 h) after pretreatment with SP600125 (20µM, 30min), followed by treatment with ATP (2.5mM, 30min).
cancer or myeloid cells (32). In our experimental settings,
the chemotherapy drugs doxorubicin and etoposide did not
trigger the IL-6 production, while paclitaxel induced a robust
expression of IL-6 in TLR4-expressing macrophages. Given that
paclitaxel can act as a direct ligand for TLR4, this drug is more
likely to promote transcriptional production of proinflammatory
cytokines than other anticancer drugs are.
Some previous studies have also shown that chemotherapeutic
drugs caused secretion of IL-1β by LPS-primed macrophages
(33, 34). However, all three tested drugs failed to induce
robust IL-1β production and caspase-1 activation in BMDMs
in combination with LPS priming in our study. However,
paclitaxel treatment, followed by a NLRP3-activating second
signal such as ATP or nigericin, markedly induced caspase-
1 activation and IL-1β secretion in BMDMs. These findings
demonstrate that paclitaxel can provide a priming signal for
NLRP3 inflammasome activation.
As a further support of this priming effect of paclitaxel, we
found that paclitaxel treatment led to phosphorylation of IκB
and JNK, confirming that paclitaxel mediates the activation of
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FIGURE 6 | Paclitaxel does not promote mitochondrial damages. (A,B) Flow cytometric analysis of BMDMs treated with paclitaxel (5µM, 3 h) or LPS (0.25µg/mL,
3 h), followed by the treatment with ATP (2.5mM, 30min), or treated with valinomycin (Val, 5µM, 30min, A), after staining with JC-1 (A) or MitoSOX (B).
(C) Quantification of MitoSOX-positive cells in (B). Asterisks indicate significant differences from untreated control (*P < 0.05, **P < 0.01; n = 2, untreated and ATP; n
= 3, others). (D) Immunoblots of culture supernatants or cellular lysates from mouse BMDMs treated with paclitaxel (5µM, 3 h) or LPS (0.25µg/mL, 3 h) after
pretreatment with cilliobrevin D (5 or 20µM, 30min), followed by treatment with ATP (2.5mM, 30min).
TLR4 downstream signaling pathways. The activation of IκB/NF-
κB signaling is responsible for the induction of transcription
of proinflammatory cytokines by paclitaxel (35). However, our
data clearly indicate that paclitaxel can trigger NLRP3-dependent
caspase-1 activation, which does not require transcription of
proinflammatory cytokines. Therefore, we focused on JNK
activation by paclitaxel treatment. Indeed, the JNK-selective
inhibitor SP600125 clearly abrogated paclitaxel/ATP-induced
caspase-1 activation. These data demonstrate that paclitaxel-
induced non-transcriptional priming is required for activation of
the NLRP3 inflammasome, although the molecular mechanism
of paclitaxel-induced priming still remains to be elucidated.
Interestingly, cell-free medium from staurosporine-treated
injured cells, probably containing danger-associated molecular
patterns (DAMPs), failed to induce robust production of
IL-1β or IL-6 in BMDMs. However, these DAMP-containing
supernatants induced marked IL-1β secretion from paclitaxel-
primed BMDMs. This result further supports the hypothesis that
paclitaxel can trigger NLRP3 inflammasome activation in the
environment adjacent to dead or injured cells. Administration
of paclitaxel to mice also led to a robust increase in IL-1β levels
in the spleens of Nlrp3-expressing but not Nlrp3-deficient mice.
These observations indicate that treatment with paclitaxel alone
is able to promote NLRP3 inflammasome activation in a certain
physiological environment.
It remains unclear whether paclitaxel-induced inflammasome
activation can affect the chemotherapeutic potential of the drugs.
Many previous studies have suggested that proinflammatory
cytokines, including IL-1β, may attenuate the efficacy of
chemotherapeutic drugs, including paclitaxel (32, 36). This
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FIGURE 7 | Paclitaxel promotes IL-1β secretion under physiological conditions. (A,B) Untreated or staurosporine (1µg/ml, 24 h)-treated A549 cells were washed and
incubated with a fresh medium for an additional 18 h to collect culture supernatants. Untreated or paclitaxel (5µM, 3 h)-pretreated BMDMs were further incubated for
18 h with conditioned medium (A549 culture supernatants + fresh medium, 2:1), and IL-1β or IL-6 levels were assayed in the supernatants by ELISA (n = 3).
(C,D) Quantification of IL-1β (C) or IL-6 (D) mRNA levels in BMDMs treated as in (A,B) (n = 3). (E,F) Quantification of IL-1β (D) or IL-6 (E) in extracts of the spleen from
Nlrp3+/+ or Nlrp3−/− mice administered the vehicle or paclitaxel (40 mg/kg) for 24 h (n = 3–5). Asterisks indicate significant differences (*P < 0.05, **P < 0.01, ***P
< 0.001). n.s., not significant.
hypothesis is supported by the observation that treatment with
an IL-1 receptor antagonist improved the antitumor effects of
chemotherapy drugs (13, 15). In this context, we can assume that
paclitaxel-mediated inflammasome activation might attenuate its
chemotherapeutic potential. On the other hand, a recent study
has shown that paclitaxel increases the antitumor immunity
via reprogramming of M2-like macrophages into cells with an
M1-like phenotype, which enhances the antitumor potential of
paclitaxel (10). Furthermore, the role of NLRP3 inflammasome in
cancer development and progression remains controversial and
conflicting. Depending on the tumor types and tissues, NLRP3
inflammasome could have either protective or aggravating effects
on tumor growth ormetastasis. Therefore, the effect of paclitaxel-
mediated inflammasome activation needs to be further evaluated
from a perspective of cancer therapy.
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